Aandeel DGX QUEST DIAGNOSTICS INCORPORATED
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Quest Diagnostics Incorporated

Aandelen

DGX

US74834L1008

Beurs gesloten - Nyse
Andere beurzen
 22:00:02 24-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
137,6 USD +0,62% Intraday-grafiek van Quest Diagnostics Incorporated +8,32% -0,24%
24/04 QUEST DIAGNOSTICS INCORPORATED : Jefferies & Co. handhaaft koopadvies ZM
24/04 QUEST DIAGNOSTICS INCORPORATED : UBS herhaalt Neutraal advies ZM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Quest Diagnostics Reports First Quarter 2024 Financial Results, Raises Guidance for Full Year 2024
Quest Diagnostics Incorporated : First Quarter 2024 View Transcript of Company Prepared Comments
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Quest Diagnostics Posts Flat Q1 Adjusted Earnings, Revenue Rises; 2024 Earnings, Revenue Guidance Raised
Earnings Flash (DGX) QUEST DIAGNOSTICS Reports Q1 Revenue $2.37B, vs. Street Est of $2.29B
Earnings Flash (DGX) QUEST DIAGNOSTICS Posts Q1 EPS $2.04, vs. Street Est of $1.86
Quest Diagnostics: Q1 Earnings Snapshot
Quest Diagnostics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024
MORNING BID AMERICAS-Tanking Tesla reports, Europe business beats
Quest Diagnostics Launches New Test to Help Assess Alzheimer's Disease Risk
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
John Chevedden Files an Exempt Solicitation Statement with Securities and Exchange Commission
Quest Diagnostics Receives Shareholder Proposal from John Chevedden
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
Quest Collaborating With Broad Clinical Labs to Assess Whole Genome Sequencing Test for Developmental Delay Disorders
Quest Diagnostics - Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's disease
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers DGX
  4. Nieuws Quest Diagnostics Incorporated
  5. Andere talen